TY - JOUR
T1 - Exercise Is Medicine for Nonalcoholic Fatty Liver Disease
T2 - Exploration of Putative Mechanisms
AU - Heinle, James Westley
AU - DiJoseph, Kara
AU - Sabag, Angelo
AU - Oh, Sechang
AU - Kimball, Scot R.
AU - Keating, Shelley
AU - Stine, Jonathan G.
N1 - Publisher Copyright:
© 2023 by the authors.
PY - 2023/6
Y1 - 2023/6
N2 - Exercise remains a key component of nonalcoholic fatty liver disease (NAFLD) treatment. The mechanisms that underpin improvements in NAFLD remain the focus of much exploration in our attempt to better understand how exercise benefits patients with NAFLD. In this review, we summarize the available scientific literature in terms of mechanistic studies which explore the role of exercise training in modulating fatty acid metabolism, reducing hepatic inflammation, and improving liver fibrosis. This review highlights that beyond simple energy expenditure, the activation of key receptors and pathways may influence the degree of NAFLD-related improvements with some pathways being sensitive to exercise type, intensity, and volume. Importantly, each therapeutic target of exercise training in this review is also the focus of previous or ongoing drug development studies in patients with nonalcoholic steatohepatitis (NASH), and even when a regulatory-agency-approved drug comes to market, exercise will likely remain an integral component in the clinical management of patients with NAFLD and NASH.
AB - Exercise remains a key component of nonalcoholic fatty liver disease (NAFLD) treatment. The mechanisms that underpin improvements in NAFLD remain the focus of much exploration in our attempt to better understand how exercise benefits patients with NAFLD. In this review, we summarize the available scientific literature in terms of mechanistic studies which explore the role of exercise training in modulating fatty acid metabolism, reducing hepatic inflammation, and improving liver fibrosis. This review highlights that beyond simple energy expenditure, the activation of key receptors and pathways may influence the degree of NAFLD-related improvements with some pathways being sensitive to exercise type, intensity, and volume. Importantly, each therapeutic target of exercise training in this review is also the focus of previous or ongoing drug development studies in patients with nonalcoholic steatohepatitis (NASH), and even when a regulatory-agency-approved drug comes to market, exercise will likely remain an integral component in the clinical management of patients with NAFLD and NASH.
UR - http://www.scopus.com/inward/record.url?scp=85161361240&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85161361240&partnerID=8YFLogxK
U2 - 10.3390/nu15112452
DO - 10.3390/nu15112452
M3 - Review article
C2 - 37299416
AN - SCOPUS:85161361240
SN - 2072-6643
VL - 15
JO - Nutrients
JF - Nutrients
IS - 11
M1 - 2452
ER -